Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF,European Journal of Heart Failure

当前位置： X-MOL 学术 › Eur. J. Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF
European Journal of Heart Failure ( IF 18.2 ) Pub Date : 2021-11-11 , DOI: 10.1002/ejhf.2381
Jawad H Butt _{1,

2} , Kieran F Docherty ₁ , Pardeep S Jhund ₁ , Rudolf A de Boer ₃ , Michael Böhm ₄ , Akshay S Desai ₅ , Jonathan G Howlett ₆ , Silvio E Inzucchi ₇ , Mikhail N Kosiborod ₈ , Felipe A Martinez ₉ , Jose C Nicolau ₁₀ , Mark C Petrie ₁ , Piotr Ponikowski ₁₁ , Olof Bengtsson ₁₂ , Anna Maria Langkilde ₁₂ , Morten Schou ₁₃ , Mikaela Sjöstrand ₁₂ , Scott D Solomon ₅ , Marc S Sabatine _{5,

14} , John J V McMurray ₁ , Lars Køber ₂

Affiliation

British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Department of Cardiology, University Medical Center and University of Groningen, Groningen, The Netherlands.
Department of Internal Medicine III, Saarland University Hospital, Saarland University, Homburg, Germany.
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Cumming School of Medicine and Libin Cardiovascular Institute, University of Calgary, Calgary, Canada.
Section of Endocrinology, Yale School of Medicine, New Haven, CT, USA.
Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City; The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Universidad Nacional de Córdoba, Córdoba, Argentina.
Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Center for Heart Diseases, University Hospital, Wroclaw Medical University, Wrocław, Poland.
Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Department of Cardiology, Herlev-Gentofte University Hospital, Herlev, Denmark.
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Among patients with heart failure (HF) and reduced ejection fraction (HFrEF), those with atrial fibrillation (AF) may respond differently to certain treatments than patients without AF. We investigated the efficacy and safety of dapagliflozin in patients with HFrEF with and without AF in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF). We also examined the effect of dapagliflozin on new-onset AF.

中文翻译：

射血分数降低的心力衰竭中达格列净和心房颤动：来自 DAPA-HF 的见解

在患有心力衰竭 (HF) 和射血分数降低 (HFrEF) 的患者中，患有心房颤动 (AF) 的患者对某些治疗的反应可能与没有 AF 的患者不同。我们在达格列净和预防心力衰竭不良结局试验 (DAPA-HF) 中调查了达格列净对伴有和不伴有 AF 的 HFrEF 患者的疗效和安全性。我们还检查了达格列净对新发房颤的影响。

更新日期：2021-11-11

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>